NBRV shares plunged, -14% today. Let's take a look:

Nabriva Therape Ads (NBRV) is trading -14% lower at $3.29 today.

Recent news:
- Nabriva Therapeutics plc (NASDAQ:NBRV) has seen a significant drop in short interest.
- The company has announced a 1-for-25 reverse stock split.

Nabriva Therape Ads has been trading between a 52-week high of $35 and a 52-week low of $3.75. The stock has a market cap of $219 Million.

Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETA® (lefamulin injection, lefamulin tablets), the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP). Nabriva Therapeutics is also developing CONTEPO™ (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis.